Redmond WL - Search Results

1

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

Linch SN, McNamara MJ, Redmond WL. Linch SN, et al. Among authors: redmond wl. Front Oncol. 2015 Feb 16;5:34. doi: 10.3389/fonc.2015.00034. eCollection 2015. Front Oncol. 2015. PMID: 25763356 Free PMC article. Review.

2

Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.

Ruby CE, Redmond WL, Haley D, Weinberg AD. Ruby CE, et al. Among authors: redmond wl. Eur J Immunol. 2007 Jan;37(1):157-66. doi: 10.1002/eji.200636428. Eur J Immunol. 2007. PMID: 17183611

3

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.

Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. Redmond WL, et al. J Immunol. 2007 Dec 1;179(11):7244-53. doi: 10.4049/jimmunol.179.11.7244. J Immunol. 2007. PMID: 18025166

4

Targeting OX40 and OX40L for the treatment of autoimmunity and cancer.

Redmond WL, Weinberg AD. Redmond WL, et al. Crit Rev Immunol. 2007;27(5):415-36. doi: 10.1615/critrevimmunol.v27.i5.20. Crit Rev Immunol. 2007. PMID: 18197805 Review.

5

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. Gough MJ, et al. Among authors: redmond wl. Cancer Res. 2008 Jul 1;68(13):5206-15. doi: 10.1158/0008-5472.CAN-07-6484. Cancer Res. 2008. PMID: 18593921

6

The role of OX40-mediated co-stimulation in T-cell activation and survival.

Redmond WL, Ruby CE, Weinberg AD. Redmond WL, et al. Crit Rev Immunol. 2009;29(3):187-201. doi: 10.1615/critrevimmunol.v29.i3.10. Crit Rev Immunol. 2009. PMID: 19538134 Free PMC article. Review.

7

Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.

Redmond WL, Gough MJ, Weinberg AD. Redmond WL, et al. Eur J Immunol. 2009 Aug;39(8):2184-94. doi: 10.1002/eji.200939348. Eur J Immunol. 2009. PMID: 19672905 Free PMC article.

8

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD. Gough MJ, et al. Among authors: redmond wl. J Immunother. 2010 Oct;33(8):798-809. doi: 10.1097/CJI.0b013e3181ee7095. J Immunother. 2010. PMID: 20842057 Free PMC article.

9

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA. Jensen SM, et al. Among authors: redmond wl. Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Semin Oncol. 2010. PMID: 21074068 Free PMC article. Review.

10

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.

Redmond WL, Triplett T, Floyd K, Weinberg AD. Redmond WL, et al. PLoS One. 2012;7(4):e34467. doi: 10.1371/journal.pone.0034467. Epub 2012 Apr 4. PLoS One. 2012. PMID: 22496812 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results